Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoV-mMAP
- Development stage
- Preclinical
- Lead developer
- epitoMAP
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
CoV-mMAP is a synthetic peptide vaccine candidate developed by epitoMAP. It is designed as a pan-coronavirus vaccine, targeting conserved epitopes across the coronavirus family to provide broad-spectrum immunity. The vaccine's design aims to remain effective against emerging viral mutations and specifically to mitigate the risk of antibody-dependent enhancement (ADE), a common complication in coronavirus vaccine development. CoV-mMAP is being explored for both human applications, such as COVID-19, and veterinary applications, specifically feline infectious peritonitis (FIP) in cats.
- Other names
- epitoMAP pan-coronavirus vaccineCoV-mMAP synthetic peptide vaccine
Beyond the preview
Go deeper on CoV-mMAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoV-mMAP.